Comparative and Combined Efficacy of Doxazosin and Enalapril in Hypertensive Patients

References

• Talseth T, Westlie L, Daae L. Doxazosin and atenolol as monotherapy in mild and moderate hypertesion: a randomised, parallel study with a three-year follow-up. Am. Heart J. 1991; 121: 280–285
   PubMed Web of Science ®Google Scholar
• deLame P A, Droussin A M, Thomson M, Verhaest L, Wallaoe S. The effects of enalapril on hypertension and quality of life. A large multicentre study in Belgium. Acta Cardiol. 1989; 44: 289–302
   PubMed Web of Science ®Google Scholar
• Ferrara L A, Di Marino L, Russo O, Marotta T, Mancini M. Doxazosin and captopril in mildly hypercholesterolemic hypertensive patients. Hypertension 1993; 21: 97–104
   PubMed Web of Science ®Google Scholar
• Perani G, Muggia C, Martignoni A, Bongarzoni A, Radaelli A, Testa F, Finardi G. Increase in plasma HDL-cholesterol in hypertensive patients treated with enalapril. Clin. Therapeutics 1987; 9: 635–639
   PubMed Web of Science ®Google Scholar
• Campbell S F, Davey M J. Doxazosin, a case history. Drug Design and Delivery 1986; 1: 83–89
   PubMedGoogle Scholar
• Veltmar A, Gohlke P, Ungar T. From tissue angiotensin converting enzyme inhibition to antihypertensive effect. Am. J. Hypertens. 1991; 4: 263S–269S
   PubMed Web of Science ®Google Scholar
• Saxena P R. Interaction between the renin-angiotensin-aldosterone and sympathetic nervous system. J. Cardiovasc. Pharmacol. 1992; 19: S80–S88
   PubMed Web of Science ®Google Scholar
• Marwood J, Tierney G, Stokes G. Investigations into interactions between doxazosin and enalapril at α1-adrenoceptors in anaesthetized rats. Clin. Exp. Pharmacol. Physiol. 1991; 18: 231–236
   PubMed Web of Science ®Google Scholar
• Marwood J, Tierney G, Stokes G. Interactions between enalapril and doxazosin at rat tail artery α1-adrenoceptors. J. Cardiovasc. Pharmacol. 1991; 17: 1–7
   PubMedGoogle Scholar
• Marwood J F, Tierney G, Stokes G S. A study of the interaction between the hypotensive actions of doxazosin and enalapril in anaesthetized rats. J. Hypertension 1992; 10: 265–270
   PubMed Web of Science ®Google Scholar
• Neels H M, van Sande M E, Scharpe S L. Sensitive colorimetric assay for angiotensin converting enzyme in serum. Clin. Chem. 1983; 29: 1399, 1403
   PubMed Web of Science ®Google Scholar
• Smith P K, Krohn R I, Hermanson G T, et al. Measurement of protein using bicinchoninic acid. Anal. Biochem. 1985; 150: 76–85
   PubMed Web of Science ®Google Scholar
• Walker B R, Shah R S, Ramanthan K B, Vanov S K, Helfant R H. Guanabenz and methyldopa on hypertension and cardiac performance. Clin. Pharmacol. Ther. 1977; 22: 868–874
   PubMed Web of Science ®Google Scholar
• Bainbridge A D, Elliott H L, Reid J L. The interaction between the α-adrenoceptor antagonist doxazosin and the angiotensin converting enzyme inhibition enalapril. Br. J. Clin. Pharmacol. 1991; 31: 569P
   Google Scholar
• Johnston C I, Jackson B, McGrath B, Matthews G, Arnolda L. Relationship of antihypertensive effect on enalapril to serum MK-422 levels and angiotensin converting enzyme inhibition. J. Hypertension 1983; 1(Suppl 1)71–75
   Google Scholar
• Stokes G S, Monaghan J C, Marwood J F, Okoro E O, Johnston H. Increase in serum total angiotensin-converting enzyme activity with enalapril therapy in humans: a controlled trial. Clin. Exp. Pharmacol. Physiol. 1992; 19: 297–299
   PubMed Web of Science ®Google Scholar
• Arzilli F, Magagna A, Giovannetti R., Nuccorini A, Salvetti A. Acute dose-response curve of enalapril in renovascular hypertensives. Am. J. Hypertension 1988; 1(suppl 3)75S–78S
   PubMed Web of Science ®Google Scholar
• Biollaz J, Burnier M, Turini G A, Brunner D B, Porchet M, Gomez H J, et al. Three new long-acting converting-enzyme inhibitors: relationship between plasma converting-enzyme activity and response to angiotensin. Clin. Pharmacol. Ther. 1981; 29: 665–670
   PubMed Web of Science ®Google Scholar
• Nussberger J, Juilherat L, Perret F, Waeber B, Bellet M, Brunner J, Menard J. Need for plasma angiotensin measurements to investigate converting enzyme inhibition in humans. Am. Heart J. 1989; 117: 717–722
   PubMed Web of Science ®Google Scholar
• Waeber B, Nussberger J, Juillerat L, Brunner H R. Angiotensin converting enzyme inhibition: discrepancy between antihypertensive effect and suppression of enzyme activity. J. Cardiovasc. Pharmacol. 1989; 14(suppl 4)S53–S59
   PubMedGoogle Scholar
• Taylor S H, Lee P S, Sharma S K. A comparison of doxazosin and enalapril in the treatment of mild and moderate essential hypertension. Am. Heart J. 1988; 116: 1820–1825
   PubMed Web of Science ®Google Scholar
• Elliott H L, Meredith P A, Sumner D J, McLean K, Reid J L. A pharmacodynamic and pharmacokinetic assessment of a new α-adrenoceptor antagonist, doxazosin (UK 33274) in normotensive subjects. Br. J. Clin. Pharmacol. 1982; 13: 699–703
   PubMed Web of Science ®Google Scholar
• Smyth P, Pringle S, Jackson G, Lorimer A R. 24–hour control of blood pressure by once daily doxazosin: a multicentre double-blind comparison with placebo. Eur. J. Clin. Pharmacol. 1988; 34: 613–618
   PubMed Web of Science ®Google Scholar
• Dzau V J. Circulating versus local renin-angiotensin system in cardiovascular homeostasis. Circulation 1988; 77: 4–13, Suppl. 1
   PubMed Web of Science ®Google Scholar
• Vicault E, Hou X. Arteriolar constriction and local renin-angiotensin system in rat microcirculation. Hypertension 1993; 21: 491–497
   PubMed Web of Science ®Google Scholar
• Jones R I, Hornung R S, Cashman P MM, Raftery E B. Effect of enalapril at rest, during tilt, static and dynamic exercise in systemic hypertension. Am. J. Cardiol. 1985; 55: 1534–1538
   PubMed Web of Science ®Google Scholar
• Pool J L. Plasma lipid lowering effects of doxazosin, a new selective alpha, adrenergic inhibitor for systemic hypertension. Am. J. Cardiol. 1987; 59: 46G–50G
   PubMed Web of Science ®Google Scholar
• Frick M H, Cox D A, Humanen P, et al. Serum lipid changes in a one-year, multicentre, double-blind comparison of doxazosin and atenolol for mild to moderate essential hypertension. Am. J. Cardiol. 1987; 59: 61G–67G
   PubMed Web of Science ®Google Scholar